Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL
May 25, 2024
Source: drugdu
99
Sucralfate is used to treat stomach ulcers,GERD, radiation proctitis, and stomach inflammation and to prevent stress ulcers.
Strides Pharma Science (Strides) recently announced that its stepdown wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Carafate 1gm/10mL of AbbVie. Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.
Sucralfate Oral Suspension, 1gm/10 mL has a market size of ~US$ 124Mn as per IQVIA (March 2024). The Sucralfate Oral Suspension, 1gm/10 mL will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India.
https://www.expresspharma.in/strides-receives-usfda-approval-for-sucralfate-oral-suspension-1gm-10-ml
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- the dawn of treatment for multiple myeloma! September 21, 2024
- Nat Microbiol | Liu Wei/Li Hao reveal new mechanism of bile acid protection against SFTSV (fever with thrombocytopenia syndrome) infection September 21, 2024
- 全球及中国在长效术后镇痛制剂领域的市场需求不断增长 September 21, 2024
- 豪掷84亿!全球心血管巨头又一收购 September 21, 2024
- Can Increased Investment in Cell Therapy Drive CAR-T Product Growth? September 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
